Table 2.
Tumor characteristics and treatment for 7,001 patients with oligodendrogliomas from the SEER database, 1973–2013
| Variables | Overall | Pediatric | Adult | p-value |
|---|---|---|---|---|
| N (%) | 7,001 | 455 (6.5) | 6,546 (93.5) | – |
| Primary site, N (%)** | ||||
| Occipital lobe | 124 (1.9) | 13 (3.5) | 111 (1.8) | 0.01 |
| Parietal lobe | 741 (11.2) | 59 (15.6) | 682 (10.9) | <0.001 |
| Temporal lobe | 1,229 (18.5) | 136 (36.1) | 1,093 (17.5) | <0.001 |
| Frontal lobe | 3,491 (52.6) | 114 (30.2) | 3,377 (53.9) | <0.001 |
| Overlapping lesion | 790 (11.9) | 33 (8.8) | 757 (12.1) | 0.08 |
| Brain, NOS | 260 (3.9) | 22 (5.8) | 238 (3.8) | 0.03 |
| Tumor size, N (%)** | ||||
| Under 2 cm | 198 (8.3) | 29 (15.8) | 169 (7.6) | <0.001 |
| 2–4 cm | 963 (40.3) | 104 (56.8) | 859 (39.0) | <0.001 |
| Over 4 cm | 1,227 (51.4) | 50 (27.3) | 1,177 (53.4) | <0.001 |
| Tumor grade, N (%) | ||||
| Stage II | 5,245 (74.9) | 410 (90.1) | 4,835 (73.9) | <0.001 |
| Stage III | 1,756 (25.1) | 45 (9.9) | 1,711 (26.1) | <0.001 |
| Treatment, N (%)** | ||||
| Neither | 675 (9.8) | 30 (6.6) | 645 (10.0) | 0.02 |
| Radiation only | 544 (7.9) | 14 (3.1) | 530 (8.3) | <0.001 |
| Surgery only | 2,917 (42.5) | 319 (70.6) | 2,598 (40.5) | <0.001 |
| Both | 2,733 (39.8) | 89 (19.7) | 2,644 (41.2) | <0.001 |
Note:
**
Data presented for patients with available information only.
Abbreviations: SEER, Surveillance, Epidemiology, and End Results; N, number; NOS, not otherwise specified.